These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37289304)

  • 21. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.
    Botrel TEA; Clark LGO; Paladini L; Clark OAC
    BMC Cancer; 2016 Aug; 16(1):677. PubMed ID: 27558497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis.
    Dongpo S; Zhengyao Z; Xiaozhuo L; Qing W; Mingming F; Fengqun M; Mei L; Qian H; Tong C
    World Neurosurg; 2022 Apr; 160():e61-e79. PubMed ID: 34973444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
    Antoniotti C; Germani MM; Rossini D; Lonardi S; Pietrantonio F; Santini D; Marmorino F; Allegrini G; Daniel F; Raimondi A; Borelli B; Zaniboni A; Conca V; Abraham J; Spetzler D; Maiello E; Boccaccino A; Passardi A; Giordano M; Tamburini E; Korn MW; Masi G; Cremolini C
    Eur J Cancer; 2022 May; 167():23-31. PubMed ID: 35366570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Zhou Y; He M; Li R; Peng Y; Li F; Li S; Yang M
    Biomed Res Int; 2021; 2021():5537899. PubMed ID: 34532503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.
    Ren T; Wang S; Shen Z; Xu C; Zhang Y; Hui F; Qi X; Zhao Q
    Drug Saf; 2021 Jan; 44(1):29-40. PubMed ID: 33180265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib plus bevacizumab versus erlotinib alone in patients with
    Deng W; Wang K; Jiang Y; Li D; Bao C; Luo J; Liu L; Huang B; Kong J
    BMJ Open; 2022 Aug; 12(8):e062036. PubMed ID: 35985780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials.
    Lv C; Wu S; Zheng D; Wu Y; Yao D; Yu X
    Cancer Biother Radiopharm; 2013 Sep; 28(7):501-9. PubMed ID: 23768086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis.
    Yang T; Wang K; Cao Y; Wen J; Wei S; Li H; Yang X; Xiao T
    BMJ Open; 2021 Feb; 11(2):e039461. PubMed ID: 33589446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang S; Mao XD; Wang HT; Cai F; Xu J
    BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.
    Zhu Y; Liu C; Xu Z; Zou Z; Xie T; Xing P; Wang L; Li J
    Chin Med J (Engl); 2023 Nov; 136(21):2551-2561. PubMed ID: 37160733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes and immunological evaluation of toripalimab combination for cancer treatment: A systematic review and meta-analysis of randomized controlled trials.
    Li J; Zhang H; Zhu H; Li H
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111176. PubMed ID: 37948860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis.
    Huang P; Guo ZK; Xue ZT
    Medicine (Baltimore); 2023 Jul; 102(29):e34386. PubMed ID: 37478250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC; Ning JY; Chen HB
    Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Martín M; Loibl S; Hyslop T; De la Haba-Rodríguez J; Aktas B; Cirrincione CT; Mehta K; Barry WT; Morales S; Carey LA; Garcia-Saenz JA; Partridge A; Martinez-Jañez N; Hahn O; Winer E; Guerrero-Zotano A; Hudis C; Casas M; Rodriguez-Martin C; Furlanetto J; Carrasco E; Dickler MN; ; ;
    Eur J Cancer; 2019 Aug; 117():91-98. PubMed ID: 31276981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
    Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
    JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.